GGT6

Across TCGA pan-cancer cohorts, GGT6 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GGT6 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GGT6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GGT6 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where GGT6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.984	0.452	.006	26	view →
LUAD	DFS	Median	II,III,IV	0.364	0.697	.004	25	view →
LSCC	DFS	Quartile	All	0.650	0.186	.026	4	view →
HNSC	OS	Median	All	0.923	0.772	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GGT6–PDAC (DFS)

Open the PDAC breakdown →